Thromb Haemost 2010; 104(05): 931-940
DOI: 10.1160/TH10-03-0151
Review Article
Schattauer GmbH

Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A

A critical literature review
Massimo Franchini
1  Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliero-Universitaria di Parma, Italy
Giuseppe Lippi
2  U.O. di Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy
› Author Affiliations
Further Information

Publication History

Received: 03 March 2010

Accepted after major revision: 03 July 2010

Publication Date:
24 November 2017 (online)


The development of inhibitors that neutralise the function of factor VIII (FVIII) is currently not only the most challenging complication associated with the treatment of haemophilia A but it also increases the disease-related morbidity as bleeding episodes do not respond to standard therapy. The main short-term goal of the treatment of inhibitor patients is to control bleeding episodes while the long-term one is to permanently eradicate the inhibitor by immune tolerance induction, particularly in the case of high-titer antibodies. Due to some in vitro studies and clinical observations, some investigators have suggested that FVIII concentrates containing von Willebrand factor (VWF) may be less immunogenic than high-purity or recombinant FVIII products. It has also been suggested that success rates for immune tolerance induction are higher when plasma-derived FVIII products are used. The currently available data from laboratory and clinical studies on the role of VWF in inhibitor development and eradication in haemophilia A is critically analysed in this review. As a result, we have not found definitive evidence supporting a role for product type on inhibitor incidence and inhibitor eradication in haemophilia A patients.